Id |
Subject |
Object |
Predicate |
Lexical cue |
T971 |
0-68 |
Sentence |
denotes |
Medication class Medication Sourcea Indirect GI adverse events Other |
T972 |
69-132 |
Sentence |
denotes |
Nausea/vomiting Abdominal pain Diarrhea Jaundice Hepatotoxicity |
T973 |
133-328 |
Sentence |
denotes |
Antiviral Lopinavir/ritonavir FDA/ manufacturer's label110 HIV Nausea (5%–16%); vomiting (children 21%; adults 2%–7%) Reported 1%–11% 7%–28%; greater with once-daily dosing — Increased serum ALT: |
T974 |
329-380 |
Sentence |
denotes |
1%–11%; hepatitis including AST/ALT/GGT elevations: |
T975 |
381-574 |
Sentence |
denotes |
4%; hyperbilirubinemia (children 3%; adults 1%) Dysgeusia (children 22%; adults <2%); hyperamylasemia (3%–8%), dyspepsia (<6%), increased lipase (3%–5%), flatulence (1-4%), gastroenteritis (3%) |
T976 |
575-619 |
Sentence |
denotes |
NIH Liver Tox111 HIV Range from mild to ALF. |
T977 |
620-642 |
Sentence |
denotes |
Recovery takes 1–2 mo. |
T978 |
643-679 |
Sentence |
denotes |
Do not re-challenge with medication. |
T979 |
680-715 |
Sentence |
denotes |
Monitor for exacerbation of HBV/HCV |
T980 |
716-783 |
Sentence |
denotes |
Momattin,105 2019 MERS Prevalence of GI AEs not reported in this SR |
T981 |
784-868 |
Sentence |
denotes |
Yao,106 2020 SARS/MERS AEs not reported in this SR (can check primary studies) SARS: |
T982 |
869-931 |
Sentence |
denotes |
2 retrospective cohort studies (combined with steroids); MERS: |
T983 |
932-1060 |
Sentence |
denotes |
1 RCT combined with IFN, 1 retrospective cohort combined with IFN/ribavirin, and 2 case reports also combined with IFN/ribavirin |
T984 |
1061-1095 |
Sentence |
denotes |
Remdesivir Al-Tawfiq,107 2020 MERS |
T985 |
1096-1117 |
Sentence |
denotes |
Sheahan,108 2020 MERS |
T986 |
1118-1392 |
Sentence |
denotes |
Antimalarial Chloroquine FDA/ manufacturer's label/NIH Liver Tox111,112 Malaria Reported; frequency not defined Abdominal cramps reported; frequency not defined Reported; frequency not defined Rarely linked to aminotransferase elevations or clinically apparent liver injury. |
T987 |
1393-1605 |
Sentence |
denotes |
In patients with AIP or PCT, it can trigger an attack with fever and serum aminotransferase elevations, sometimes resulting in jaundice Minor metabolism by liver (∼30%); mostly excreted in urine Likelihood score: |
T988 |
1606-1665 |
Sentence |
denotes |
D (possible rare cause of clinically apparent liver injury) |
T989 |
1666-1990 |
Sentence |
denotes |
Hydroxychloroquine113 FDA / Manufacturer's label Malaria / SLE Reported; frequency not defined Reported; frequency not defined Reported; frequency not defined Same as chloroquine above; can be exchanged with chloroquine as most reactions are hypersensitivity and no known cross reactivity to hepatic injury Likelihood score: |
T990 |
1991-2050 |
Sentence |
denotes |
D (possible rare cause of clinically apparent liver injury) |